Stock Analiz

Cardio Diagnostics Holdings, Inc. CDIO

Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 2022 · data as of November 13, 2026

$1.89Market cap $6M
Open the interactive analysis →

Cardio Diagnostics Holdings, Inc. (CDIO) is a healthcare company listed in the US with a market value of about $6M. In the twelve months to September 30, 2026 it had revenue of $15185 and net income of -$6M, a net margin of -42721.9%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -92%.

About Cardio Diagnostics

Cardio Diagnostics is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances, IPO year 2022. Revenue went from $901 in 2021 to $14825 in 2025, growth of about 101.4% a year. It was profitable in 0 of the last 5 years in our data. Its share count rose by 1602% over three years (dilution for shareholders). It spends 4325% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S368.4
P/B1.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-103.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-57.5%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-135300.0%
ROIC (5-yr avg.)-91.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 5 years

Fiscal yearTTM20252024202320222021
Revenue$15185$14825$34890$17065$950$901
Net income-$6M-$6M-$8M-$8M-$5M-$620448
Free cash flow-$6M-$6M-$5M-$6M——
EPS (diluted)$-2.53$-3.71$-9.35$-19.80$-45.30$-15.90
Net margin-42721.9%-43832.5%-24028.2%-49087.8%-490600.0%-68862.1%
ROIC—-69.2%-66.2%-158.9%-105.7%-58.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Cardio Diagnostics pay a dividend?

Not currently.

Is Cardio Diagnostics a good stock to buy?

We do not give buy or sell advice. Cardio Diagnostics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.